Articles tagged "Heart/lung transplantation"

2017 American Transplant Congress
Increased Ischemic Inflammation Induces Recipient Endogenous Memory CD4 Cell-Graft Dendritic Cell Interactions to Provide Help for Activation of Endogenous Memory CD8 T Cells.
H. Tsuda, T. Tanaka, C. Su, A. Valujskikh, R. Fairchild.
Immunology, Cleveland Clinic, Cleveland, OH
Memory T cells provide protection against recurrent pathogens, but memory T cells with donor-reactivity pose a major barrier to successful allograft transplant and tolerance induction.…
2016 American Transplant Congress
Indefinite Survival of Fully MHC-Mismatched Murine Cardiac Allografts by Combination of Anti-BTLA mAb (6B2) and Anti-PD-1 mAb (PIM-2).
E. Yin,^1,2 M. Uchiyama,^1,3 X. Jin,^1,4 T. Shimokawa,³ H. Yagita,⁵ M. Niimi.¹
¹Surgery, Teikyo University, Tokyo, Japan; ²Cardiovascular Surgery, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China; ³Cardiovascular Surgery, Teikyo University, Tokyo, Japan; ⁴Thoracic Surgery, The 3rd Affiliated Hospital of Harbin Medical University, Harbin, China; ⁵Immunology, Juntendo University Hospital, Tokyo, Japan.
Background: The co-inhibitory receptor B and T lymphocyte attenuator (BTLA) and Programmed death (PD)-1 had been suggested to have immunomodulatory activity. This study investigated the…
2016 American Transplant Congress
CD4 T Cell Mediated Help Is Required for Intra-Allograft Proliferation of Endogenous Memory CD8 T Cells and Their Ability to Mediate Rejection of Cardiac Allografts Subjected to Prolonged Ischemia.
H. Tsuda, T. Tanaka, C. Su, A. Valujskikh, R. Fairchild.
Immunology, Cleveland Clinic, Cleveland, OH.
Memory T cells are critical components to protective immunity against recurrent pathogens, but memory T cells with donor-reactivity pose a major barrier to successful transplantation…
2016 American Transplant Congress
Increasing Volume and Improved Survival in Solid Organ Transplantation for Amyloidosis – An Analysis of the UNOS Database.
J. Jaramillo,¹ J. Stehlik,¹ J. Fang,¹ R. Al-Dulaimi,¹ E. Gilbert,¹ S. Drakos,¹ O. Wever-Pinzon,¹ C. Selzman,¹ S. McKellar,¹ T. Kovacsovics,² J. Abraham,² M. Maurer,³ J. Nativi-Nicolau.¹
¹University of Utah, Salt Lake City, UT; ²Huntsman Cancer Institute, Salt Lake City, UT; ³New York-Presbyterian/Columbia University, New York, NY.
Background: Amyloidosis is a rare disease that results from accumulation of inappropriately folded proteins causing organ failure and poor prognosis. In the last decade several…
2016 American Transplant Congress
The Impact of Complement Binding Donor Specific Antibodies in the First Year After Heart Transplantation.
J. Patel, M. Kittleson, D. Chang, T. Aintablian, A. Velleca, D. Ramzy, L. Czer, J. Kobashigawa.
Cedars-Sinai Heart Institute, Los Angeles, CA.
Background: The development of donor specific antibodies (DSA) after heart transplant has been associated with poor outcome. We now have the ability to assess the…
2016 American Transplant Congress
Gender Mismatch in the UNOS Heart Transplant Database: Not a Factor in Younger Heart Transplant Patients.
J. Kobashigawa, M. Kittleson, L. Czer, T. Aintablian, E. Passano, D. Chang, F. Esmailian, J. Patel.
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: Through several registries, it has been found that gender mismatch, female donor-to-male recipient (F/M) compared to male donor-to-male recipient (M/M) has lower survival. These…
2016 American Transplant Congress
The Largest Single Center Experience with Total Artificial Heart Implantation: Characterization of Outcome.
F. Arabia, M. Kittleson, L. Czer, D. Chang, T. Aintablian, E. Passano, G. Rodriguez, C. Runyon, J. Kobashigawa, J. Moriguchi.
Cedars-Sinai Heart Institute, Los Angeles, CA.
Background: Patients with severe irreversible biventricular heart failure may require support with the total artificial heart (TAH). These patients are usually Intermacs level 1 or…
2016 American Transplant Congress
Is Donor Methamphetamine Use a Contraindication in Heart Transplantation?
M. Kittleson, J. Patel, L. Czer, A. Velleca, T. Aintablian, D. Chang, F. Esmailian, J. Kobashigawa.
Cedars-Sinai Heart Institute, Los Angeles, CA.
Background: Donor methamphetamine (meth) use has been a relative contraindication for the use of the donor hearts for patients awaiting heart transplantation. The concern is…
2016 American Transplant Congress
Intracellular OPN Is an Essential Protective Factor for Cardiac Endothelial Cell and the Long Term Heart Graft Survival.
Y. Su,^1,2,3 Z.-X. Zhang,^1,2,3 Z.-Q. Yin,¹ X.-Y. Huang,¹ A. Jevnikar.^1,2,3,4
¹Matthew Mailing Centre for Translational Transplantation Studies, Lawson Health Research Institute, London Health Sciences Centre, London Health Sciences Centre, Lodon, ON, Canada; ²Departments of Medicine, London Health Sciences Centre, Lodon, ON, Canada; ³Departments of Pathology, London Health Sciences Centre, London, ON, Canada.
[Background] Endothelial cell (EC) injury is central to cardiac allograft vasculopathy and premature graft loss. Osteopontin (OPN) is a multifunctional anti-apoptotic protein that is involved…
2016 American Transplant Congress
Outcome of the Various Pathology Grades of Antibody-Mediated Rejection After Heart Transplantation.
J. Patel, M. Kittleson, D. Chang, T. Aintablian, L. Czer, A. Trento, J. Kobashigawa.
Cedars-Sinai Heart Institute, Los Angeles, CA.
Background: The pathology scale for antibody-mediated rejection (AMR) was approved by the board of directors in 2013. The ISHLT AMR grading scale consists of pAMR…